Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
about
B-Raf and the inhibitors: from bench to bedsideThe evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibKRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentCombination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapyMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyMelanoma: oncogenic drivers and the immune systemENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngiomaNew developments in the management of advanced melanoma - role of pembrolizumabImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyReflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune ResponseCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetAdoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergyIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaUniverses collide: combining immunotherapy with targeted therapy for cancerEmerging targeted therapies for melanoma treatment (review)Pathways and therapeutic targets in melanomaOptimal management of metastatic melanoma: current strategies and future directionsEZH2 as a mediator of treatment resistance in melanomaFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeNivolumab in melanoma: latest evidence and clinical potentialControl of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrinsA randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis.Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expressionTargeting the PD-1 pathway: a promising future for the treatment of melanoma.Understanding the biology of melanoma and therapeutic implicationsOncogene withdrawal engages the immune system to induce sustained cancer regression.BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in miceCombined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challengesThe immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFαAn essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Effects of BRAF mutations and BRAF inhibition on immune responses to melanomaDabrafenib and its potential for the treatment of metastatic melanoma.Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma
P2860
Q21198860-6B68A026-973A-4729-9CAB-D587BC7CB932Q26744335-5F2F19D2-F26A-42BF-BB06-C32D95A2C734Q26751520-CA552D20-9EC0-4D58-9236-CB14C70099D0Q26769870-C8FD5B1F-468C-42E6-83A6-B86572B11421Q26771192-E3F1F3C0-9E0F-4A02-BA43-DAABCAABD31CQ26775598-2FFE86AC-7ABF-4BDC-9F75-7C446D5C66F7Q26777288-665429FE-1D8F-4024-B0B9-E1C1F499DC58Q26781931-D95D601A-CA08-4574-B1CF-9015192A1C72Q26796309-4056893B-7B5B-4A6F-B685-7B44ACDE5ADDQ26799073-BF6278C5-682D-4320-A627-8FC1B174247BQ26799864-2F8D443C-8F3B-418A-AE9A-CEC9D280C784Q26822793-1ACFA8CA-B355-4C7C-8E71-E7862970987CQ26824310-C6D3C0A8-14D2-4940-9882-AFC480E42628Q26825316-6D85741F-762E-420B-87E3-DAF843201AB6Q26829997-862D2DA1-4ECD-4C4E-896A-7DBD879FBF24Q26865736-ADC77E84-E9DC-4EF1-9B1B-8E4DD695507CQ26997338-C01EFFDB-1722-49E4-848C-0CFD2DBEF23CQ28074492-E5E8337D-9400-41F8-95E2-C6D529B6D5DFQ28119095-879DD356-0B05-478E-AE5D-696AAE3D9E85Q28258598-9935D779-EAEE-4E89-B0E0-356FFAF7C681Q29994573-E9C7F5FD-1C2D-4704-9185-CF6E86B8E628Q30274920-B7BF3539-D6CF-4BC7-BA0F-ED1D071FFF8DQ30408331-A5235CEC-F7C9-4D5E-BA9A-7CC643DB65C7Q30411499-C7E3A56F-0A90-4FCB-97C4-8A40E8DF627EQ33762053-5AD016F4-14BB-44DC-A5BE-84DC01D32E57Q33776925-C0BD0A0F-A7C7-41ED-8979-6346DCEE74CDQ33898182-9E8F5B41-9E90-4C8A-873B-276E28E79983Q33931434-9BC9366F-0C9D-4A46-8ACF-A64146637F79Q33946513-4B5F78D6-DAFF-4DC5-B206-67914EB28702Q33978378-D789D87F-25D7-4786-99A7-898D518B187CQ33987633-E07D0572-4A6A-44D4-AE5D-5162F1744D5BQ33996674-7CF4D0FF-C1B2-4A11-B269-0E014D6BB54BQ34100838-B0B81FF5-F72F-4DE5-905E-A252F1B20AA3Q34185078-5EC56E2D-FC58-4261-8C6D-335C514B724DQ34287452-67775701-6564-470C-8C6D-01B6A90BEA70Q34361976-C83751C8-A557-4DF4-8FCA-4AEF6432BA0EQ34646279-82612411-1D4A-44C4-B24C-1F35E9982B58Q34646614-53E561AC-975C-42F1-A275-B86787628EC3Q34661815-3FFED5A0-3ED6-406E-91C1-18E819644772Q34662717-C3B84D65-F599-4EB1-B7CF-237F645AE262
P2860
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Selective BRAF inhibitors indu ...... nto human metastatic melanoma.
@en
Selective BRAF inhibitors indu ...... nto human metastatic melanoma.
@nl
type
label
Selective BRAF inhibitors indu ...... nto human metastatic melanoma.
@en
Selective BRAF inhibitors indu ...... nto human metastatic melanoma.
@nl
prefLabel
Selective BRAF inhibitors indu ...... nto human metastatic melanoma.
@en
Selective BRAF inhibitors indu ...... nto human metastatic melanoma.
@nl
P2093
P50
P1476
Selective BRAF inhibitors indu ...... nto human metastatic melanoma.
@en
P2093
James S Wilmott
John F Thompson
Julie R Howle
Lauren E Haydu
Peter Hersey
Raghwa N Sharma
P304
P356
10.1158/1078-0432.CCR-11-2479
P407
P577
2011-12-12T00:00:00Z